By Matthew Roscoe •
Updated: 28 Aug 2022 • 11:55
AstraZeneca's Farxiga lowers cardiovascular death risk in heart failure patients, study shows. Image: Halawi/Shutterstock.com
AstraZeneca’s Farxiga said: “New results from a pre-specified, patient level, pooled analysis from the Phase III DAPA-HF and DELIVER trials demonstrated mortality benefit of Farxiga (dapagliflozin), compared to placebo, in patients with heart failure (HF).
“These results were presented at the European Society of Cardiology Congress 2022 in Barcelona, Spain and simultaneously published in Nature Medicine.”
It added: “The reduction in risk of cardiovascular (CV) death was consistent across pre-specified subgroups and is the first analysis to demonstrate a mortality benefit with HF medication in patients with HF across the left ventricular ejection fraction (LVEF) range.
“The analysis showed that Farxiga reduced the risk of CV death by 14 per cent (p=0.01, absolute risk reduction [ARR] 1.5 per cent) over the median follow-up of 22 months, death from any cause by 10 per cent (p=0.03, ARR 1.5 per cent), total (first and repeat) hospitalisation for HF by 29 per cent (p < 0.001, ARR 6 per cent), and the composite of death from CV causes, myocardial infarction, or stroke by 10 per cent (p=0.045, ARR 1.3 per cent), in patients with HF irrespective of LVEF.”
Farxiga is a first-in-class, oral, once-daily SGLT2 inhibitor which has been approved in adults and children aged 10 years and above for the treatment of insufficiently controlled type-2 diabetes mellitus as an adjunct to diet and exercise.
Prof. John McMurray, Professor of Medical Cardiology and Deputy Director of the Institute of Cardiovascular and Medical Sciences at the University of Glasgow, UK, said: “In this patient-level meta-analysis including over 11,000 patients with heart failure across the full range of ejection fraction, dapagliflozin reduced the risk of both cardiovascular death and heart failure hospitalisation.
“These results underpin the valuable role dapagliflozin can play in clinical practice, as we can initiate treatment right away while waiting for ejection fraction to be measured.”
Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said:“Heart failure remains one of the leading causes of death worldwide with high unmet need for some 64 million people.
“This analysis demonstrates Farxiga’s ability to treat patients across the full left ventricular ejection fraction spectrum and reduce the risk of cardiovascular death.”
According to the pharmaceutical company, “the DAPA-HF and DELIVER Phase III trials were randomised and double-blind, comparing Farxiga to placebo.
“Each trial enrolled patients with a diagnosis of HF, functional limitation, and elevated natriuretic peptides. The principal difference between the two trials was that patients with an LVEF of 40% per cent or less were randomised in DAPA-HF and those with a LVEF greater than 40% in DELIVER.
“In each trial, the studies included 11,007 individuals with HF across 20 countries.”
Thank you for taking the time to read this article. Do remember to come back and check The Euro Weekly News website for all your up-to-date local and international news stories and remember, you can also follow us on Facebook and Instagram.
Share this story
Subscribe to our Euro Weekly News alerts to get the latest stories into your inbox!
By signing up, you will create a Euro Weekly News account if you don't already have one. Review our
Originally from the UK, Matthew is based on the Costa Blanca and is a web reporter for The Euro Weekly News covering international and Spanish national news. Got a news story you want to share? Then get in touch at firstname.lastname@example.org.
Download our media pack in either English or Spanish.